|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Tyra Biosciences, Inc. (TYRA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,270,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Tyra Biosciences is an oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Co. is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR family. Co.'s lead product candidate, TYRA-300, is designed to selectively inhibit Fibroblast Growth Factor Receptor3, with an initial focus on patients with bladder cancer. In addition, Co. has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, and FGFR4-related cancers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
21,298 |
221,691 |
456,290 |
785,314 |
Total Sell Value |
$427,399 |
$3,766,874 |
$7,701,881 |
$12,216,507 |
Total People Sold |
1 |
2 |
2 |
3 |
Total Sell Transactions |
10 |
15 |
38 |
53 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hudkins Robert L. |
Chief Technology Officer |
|
2022-09-15 |
4 |
A |
$7.66 |
$7,965 |
D/D |
1,040 |
273,576 |
|
- |
|
Tada Hiroomi |
Chief Medical Officer |
|
2022-03-15 |
4 |
A |
$8.53 |
$23,044 |
D/D |
2,703 |
80,625 |
|
- |
|
Harris Todd |
Chief Executive Officer |
|
2022-03-15 |
4 |
A |
$8.53 |
$26,642 |
D/D |
3,125 |
1,699,468 |
|
- |
|
Patel Piyush R. |
Chief Development Officer |
|
2022-03-15 |
4 |
A |
$8.53 |
$20,529 |
D/D |
2,408 |
137,472 |
|
- |
|
Swanson Ronald V. |
Chief Scientific Officer |
|
2022-03-15 |
4 |
A |
$8.53 |
$26,642 |
D/D |
3,125 |
273,254 |
|
- |
|
Hudkins Robert L. |
Chief Technology Officer |
|
2022-03-15 |
4 |
A |
$8.53 |
$20,529 |
D/D |
2,408 |
272,536 |
|
- |
|
Van Den Boom Esther |
Chief Financial Officer |
|
2022-03-15 |
4 |
A |
$8.53 |
$15,346 |
D/D |
1,800 |
120,445 |
|
- |
|
Lewis Joseph |
10% Owner |
|
2021-12-17 |
4 |
B |
$13.12 |
$1,640,313 |
D/D |
125,000 |
6,448,359 |
2.45 |
- |
|
Cormorant Private Healthcare Fund Iii Lp |
Former 10% Owner |
|
2021-09-17 |
4 |
B |
$16.00 |
$5,000,000 |
I/I |
312,500 |
1,069,932 |
0.01 |
- |
|
Cormorant Private Healthcare Fund Iii Lp |
Former 10% Owner |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
757,432 |
757,432 |
|
- |
|
Canaan Partners 2020+ Co-Investment Llc |
10% Owner |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,409,991 |
473,396 |
|
- |
|
More Robert J |
Director |
|
2021-09-17 |
4 |
B |
$16.00 |
$2,500,000 |
I/I |
156,250 |
4,080,296 |
2.1 |
- |
|
More Robert J |
Director |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,811,117 |
3,924,046 |
|
- |
|
Davis Aaron I. |
10% Owner |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986,454 |
288,095 |
|
- |
|
Davis Aaron I. |
10% Owner |
|
2021-09-17 |
4 |
B |
$16.00 |
$10,000,000 |
D/D |
625,000 |
6,323,359 |
2.45 |
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
8,501 |
527,981 |
|
- |
|
Janney Daniel |
10% Owner |
|
2021-09-17 |
4 |
B |
$16.00 |
$2,500,000 |
I/I |
156,250 |
4,080,296 |
1.5 |
- |
|
Janney Daniel |
10% Owner |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,811,117 |
3,924,046 |
|
- |
|
Harris Todd |
Chief Executive Officer |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
34,007 |
1,696,343 |
|
- |
|
Van Den Boom Esther |
Chief Financial Officer |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
21,254 |
21,254 |
|
- |
|
Chen Isan |
Director |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
61,444 |
192,783 |
|
- |
|
Kjellson Nina S |
Director |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
4,409,991 |
473,396 |
|
- |
|
Shah Rajeev M. |
Director |
|
2021-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
5,986,454 |
442,721 |
|
- |
|
Shah Rajeev M. |
Director |
|
2021-09-17 |
4 |
B |
$16.00 |
$20,000,000 |
I/I |
1,250,000 |
5,297,120 |
2.25 |
- |
|
More Robert J |
Director |
|
2021-09-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
112,929 |
|
- |
|
135 Records found
|
|
Page 5 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|